Allogene Therapeutics (ALLO) Asset Writedowns and Impairment (2023 - 2025)

Allogene Therapeutics (ALLO) has 3 years of Asset Writedowns and Impairment data on file, last reported at $2.4 million in Q2 2025.

• For the quarter ending Q2 2025, Asset Writedowns and Impairment fell 52.36% year-over-year to $2.4 million; the trailing twelve-month figure through Dec 2025 stood at $2.4 million (down 89.28% YoY), and the FY2025 full-year result was $2.4 million, down 84.84% from the prior year.
• Asset Writedowns and Impairment declined to $2.4 million in Q2 2025, from $10.7 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $10.7 million in Q3 2024 to a low of $2.4 million in Q2 2025.
• A 3-year average of $6.2 million and a median of $5.8 million in 2023 frame the typical range for Asset Writedowns and Impairment.
• Peak annual rise in Asset Writedowns and Impairment reached 52.36% in 2025, while the deepest fall reached 52.36% in 2025.
• Tracing ALLO's Asset Writedowns and Impairment over 3 years: stood at $6.5 million in 2023, then jumped by 65.05% to $10.7 million in 2024, then sank by 77.8% to $2.4 million in 2025.
• Business Quant data shows ALLO's Asset Writedowns and Impairment at $2.4 million in Q2 2025, $10.7 million in Q3 2024, and $5.0 million in Q2 2024.